MetaVia Inc. Reports Q2 2025 Financial Results and Strategic Progress

Neurobo Pharmaceuticals, Inc. ( (MTVA) ) has released its Q2 earnings. Here is a breakdown of the information Neurobo Pharmaceuticals, Inc. presented to its investors.

MetaVia Inc. is a clinical-stage biotechnology company dedicated to advancing treatments for cardiometabolic diseases, with a focus on developing innovative therapies for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). In its latest earnings report for the second quarter of 2025, MetaVia highlighted significant progress in its clinical trials, including the dosing of the first patient in an extended 8-week cohort of its Phase 1 trial for DA-1726, aimed at treating obesity. The company also announced a collaboration with Syntekabio to explore additional indications for its DA-1241 compound beyond MASH.

Key financial metrics from the report indicate a notable reduction in research and development expenses, which decreased from $8.1 million in Q2 2024 to $2.3 million in Q2 2025. This reduction contributed to a decrease in total operating expenses, which fell from $10.1 million to $4.3 million over the same period. MetaVia also reported a net loss of $4.0 million for the quarter, a significant improvement from the $10.1 million loss in the previous year. The company’s cash position stood at $17.6 million as of June 30, 2025, expected to support operations into 2026.

Strategically, MetaVia is advancing its DA-1726 and DA-1241 programs. DA-1726 has shown promising results in weight reduction and glucose control, with ongoing trials expected to provide further data by the end of the year. Meanwhile, DA-1241 has demonstrated potential in reducing liver fat and inflammation, with plans to expand its therapeutic applications through AI-driven collaborations.

Looking ahead, MetaVia remains focused on achieving key clinical milestones, including the anticipated data release from the 8-week DA-1726 trial and further development of DA-1241. The company’s management is optimistic about its strategic direction and financial health, positioning MetaVia to continue its innovative work in addressing significant unmet medical needs in cardiometabolic diseases.